Bayer HealthCare’s Animal Health Division received approval from the Food and Drug Administration (FDA) to market ProstaMate™ (dinoprost tromethamine) and OvaCyst™ (gonadorelin diacetate tetrahydrate) for indications in support of reproduction management as prescribed by veterinarians. ProstaMate™ is indicated for use in cattle, swine and mares; OvaCyst™ for use in dairy cattle.
“Efficient reproduction is the cornerstone of successful dairy production and cattle herd management,” says Dr. Milo Wiltbank, Professor of Reproductive Physiology, Department of Dairy Science, University of Wisconsin. “The proper use of reproductive hormones provides veterinarians and producers effective options that will help reduce labor costs, increase the productivity of their cows and improve the efficiency of their operations.”
These two of Bayer’s newest products, acquired through the Teva acquisition, have been among the leading reproduction management product choices for veterinarians and producers for years.
“With the launch of these two products we want to support veterinarians and producers who need them,” said Dr. Dirk Ehle, Global Head of the Bayer HealthCare Animal Health Division. “Bayer HealthCare is now active in most major therapeutic areas of the animal health field, with a strong portfolio to support the health of both farm and companion animals.”
August 2, 2013 - Bayer